Acobur (@acobur) 's Twitter Profile Photo

🟢 La CE aprueba Balversa (erdafitinib) de Johnson & Johnson para el cáncer de vejiga avanzado. #Oncología #Balversa #MedicinaDePrecisión i.mtr.cool/olmgmntnat

PharmaShots - Incisive news in 3 shots (@pharmashot) 's Twitter Profile Photo

Johnson & Johnson’s Balversa (Erdafitinib) Receives the EC’s Approval to Treat Urothelial Carcinoma #johnsonandjohnson #balversa #erdafitinib #urothelialcarcinoma #regulatory #ec #approval #phase3 #thor pharmashots.com/18925/johnson-…

Johnson & Johnson’s Balversa (Erdafitinib) Receives the EC’s Approval to Treat Urothelial Carcinoma 
#johnsonandjohnson #balversa #erdafitinib #urothelialcarcinoma #regulatory #ec #approval #phase3 #thor
pharmashots.com/18925/johnson-…
BladderCancerCanada (@bladdercancerca) 's Twitter Profile Photo

We are looking for patients who have received erdafitinib (Balversa) treatment. If you would be interested in learning more and/or want to share your experience, please email [email protected] #BladderCancer #BladderCancerCanada #Balversa #erdafitinib

We are looking for patients who have received erdafitinib (Balversa) treatment. If you would be interested in learning more and/or want to share your experience, please email studies@bladdercancercanada.org #BladderCancer #BladderCancerCanada #Balversa #erdafitinib
CDA-AMC (@cda_amc) 's Twitter Profile Photo

⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur l’erdafitinib (#Balversa) dans le traitement du carcinome urothélial non résécable localement avancé ou métastatique. Échéance : 28 juin 2024 cda-amc.ca/fr/erdafitinib #ETS #HTA

⚠️Appel d’observations, patients et cliniciens⚠️ Nous sollicitons des observations sur l’erdafitinib (#Balversa) dans le traitement du carcinome urothélial non résécable localement avancé ou métastatique. 

Échéance : 28 juin 2024 cda-amc.ca/fr/erdafitinib #ETS #HTA
CDA-AMC (@cda_amc) 's Twitter Profile Photo

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on erdafitinib (#Balversa) for locally advanced unresectable or metastatic urothelial carcinoma (UC). Deadline is June 28, 2024: cda-amc.ca/erdafitinib #HTA

⚠️Call for Patient and Clinician Input⚠️ We are requesting input on erdafitinib (#Balversa) for locally advanced unresectable or metastatic urothelial carcinoma (UC). 

Deadline is June 28, 2024: cda-amc.ca/erdafitinib #HTA
Cancer Medicine - 癌症医学 (oncology) (@ferna585512412) 's Twitter Profile Photo

#erdafitinib Erdafitinib #ERDADX #urothelialcancer #bladdercancer #balversa Balversa #angiogenesis #bladdercancer #UrothelialCarcinoma WeChat : drug-international / lifesaving-medicine website : medicine-international.com

#erdafitinib Erdafitinib #ERDADX #urothelialcancer #bladdercancer #balversa Balversa #angiogenesis #bladdercancer #UrothelialCarcinoma
 WeChat : drug-international / lifesaving-medicine 
 website : medicine-international.com
Talk.Bio (@talkbionews) 's Twitter Profile Photo

🧵 Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer #JohnsonJohnson #Balversa #BladderCancer #ClinicalData #FgfrInhibitor #TargetedTherapy #UrothelialCarcinoma